BioTuesdays

Category - Markets

Catalyst
Markets

Ladenburg ups Catalyst Bioscience PT to $14.25

Ladenburg Thalmann raised its price target for Catalyst Biosciences (NASDAQ:CBIO) to $14.25 from $11 after the company modified the Phase 1/2 protocol of CB 2679d that should accelerate the timeline to initiation of a...

December 18, 2017
Restoration Robotics
Markets

Roth starts Restoration Robotics at buy

Roth Capital Partners launched coverage of Restoration Robotics (NASDAQ:HAIR) with a “buy” rating and price target of $7.50. The stock closed at $4.86 on Dec. 15. Restoration is focused on developing and commercializing...

December 18, 2017
GlycoMimetics
Markets

Stifel ups GlycoMimetics price target to $23

Stifel raised its price target for GlycoMimetics (NASDAQ:GLYC) to $23 from $17 after the company presented incremental Phase 1/2 data for GMI-1271 in both relapsed/refractory (R/R) and newly-diagnosed AML patients. The...

December 12, 2017
scPharmaceuticals
Markets

Leerink starts scPharmaceuticals at OP; PT $20

Leerink launched coverage of scPharmaceuticals (NASDAQ:SCPH) with an “outperform” rating and $20 price target. The stock closed at $14.92 on Dec 11. “The lead product, Furoscix (furosemide, diuresis for heart failure...

December 12, 2017
Diplomat Pharmacy
Markets

Leerink ups Diplomat Pharmacy to OP; PT to $23

Leerink upgraded Diplomat Pharmacy (NYSE:DPLO) to “outperform” and raised its price target to $23 from $20 after recent investor meetings with the company’s management and after considering several new developments. The...

December 11, 2017
Akebia Therapeutics Logo
Markets

BTIG starts Akebia Therapeutics at buy; PT $30

BTIG initiated coverage of Akebia Therapeutics (NASDAQ:AKBA) with a “buy” rating and price target of $30. The stock closed at $15.40 on Dec. 6. Akebia is focused on the development of Vadadustat, a novel oral, once...

December 7, 2017
inflaRx
Markets

Leerink starts InflaRx at outperform; PT $31

Leerink initiated coverage of InflaRx N.V. (NASDAQ:IFRX) with an “outperform” rating and $31 price target. The stock closed at $20.88 on Dec. 1. “InflaRx has an opportunity to generate significant shareholder value with...

December 4, 2017
Madrigal Pharmaceuticals
Markets

Roth ups Madrigal Pharma PT to $82

Roth Capital Partners raised its price target for Madrigal Pharmaceuticals (NASDAQ:MDGL) to $82 from $62 ahead of interim results in late December from the company’s Phase 2b NASH trial. Nonalcoholic steatohepatitis...

December 1, 2017
Verastem
Markets

Roth starts Verastem at buy; PT $12

Roth Capital Partners launched coverage of Verastem (NASDAQ:VSTM) with a “buy” rating and $12 price target. The stock closed at $3.66 on Nov. 29. Analyst Dr. Jotin Marango writes that his qualitative and quantitative...

November 30, 2017
Arcturus Logo
Markets

Ladenburg starts Arcturus at buy; PT $22

Ladenburg Thalmann initiated coverage of Arcturus Therapeutics (NASDAQ:ARCT) with a “buy” rating and $22 share price target. The stock closed at $8.71 on Nov. 28. Arcturus has developed a novel biodegradable lipid...

November 29, 2017